The reduction in price target by Wells Fargo, a major financial institution, could lead to a negative short-term sentiment among investors, potentially causing a decrease in Gilead Sciences' stock price. The Equal-Weight rating suggests that the analyst views the company as adequately valued at its current price, but the lowered target indicates a reassessment of the company's future growth prospects or market conditions.